• Participants must meet all of the following inclusion criteria to be enrolled in the study:

‣ Age 18-70 years old (including 18 years old and 70 years old), regardless of gender;

⁃ Can understand the study and have signed the informed consent;

⁃ Expected survival time \> 3 months;

⁃ The American Eastern Oncology Consortium (ECOG) score was 0-1;

⁃ Cd20-positive B-NHL was confirmed cytologically or histologically according to WHO 2016 criteria These include diffuse large B-cell lymphomas (including histologically transformed forms) and transformed follicular lymphomas (TFL); (For the expression status of CD20, the histological diagnosis of CD20 has been clearly documented in the past Positive subjects (diagnosis within 3 months prior to screening); Subjects without prior records, Pathological specimens provided or collected by our hospital were diagnosed as CD20 positive; Not without a clear record For those who provide or collect specimens, the researchers and sponsors will decide whether to be included according to their medical records);

⁃ For recurrent or refractory B-cell non-Hodgkin lymphoma, subjects must have at least been treated with anthracene Treatment with cyclodrugs and rituximab (or other CD20-targeting drugs), and have already received them At least two cycles of treatment; Refractory is defined as the best response to the most recent treatment regimen as disease progression, or the last treatment The optimal response of the regimen (at least 2 cycles) was stable disease with a duration of less than 6 months.

⁃ Does not meet the criteria for autologous hematopoietic stem cell transplantation (auto-HSCT) or is unwilling to perform autologous transplantation Patients with recurrence or progression after blood stem cell transplantation or autologous hematopoietic stem cell transplantation;

⁃ The venous access required for mononuclear cell collection can be established, and the hemoglobin is ≥70 g/L and neutral Granulocyte ≥ 1.0×109/L, platelet ≥50×109

‣ /L, a single nucleus can be performed by the investigator's judgment Cell collection;

⁃ Evaluable lesions identified according to the 2014 Lugano efficacy evaluation criteria;

‣ Organ functions meet the following requirements:

• The investigator assessed sufficient bone marrow function to receive lymphocyte clearance chemotherapy;

∙ Serum creatinine ≤1.5× upper limit of normal (ULN) or creatinine clearance (Cockcroft and Gault) \> 30 mL/min/1.73 m2

• ;

∙ Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3× ULN (ALT and AST in patients with liver metastasis ≤5×ULN);

∙ Total bilirubin ≤2.0 × ULN (for patients with Gilbert's syndrome or lymphoma invading the liver

• ≤3 × ULN);

∙ Lung function: ≤CTCAE grade 1 dyspnea and oxygen saturation of basic finger pulse in indoor air environment Sum degree ≥92%;

∙ Cardiac function: Normal diastolic function, echocardiography or radiation within 1 month prior to enrollment Sexual nuclide active angiography (MUGA) revealed left ventricular ejection fraction (LVEF) ≥ 50%, no clinically significant pericardial effusion. Exclusion criteria Subjects who meet any of the following criteria will not be enrolled in this study